BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21164510)

  • 1. Drug discovery: New Btk inhibitor holds promise.
    Hendriks RW
    Nat Chem Biol; 2011 Jan; 7(1):4-5. PubMed ID: 21164510
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
    Wu H; Wang W; Liu F; Weisberg EL; Tian B; Chen Y; Li B; Wang A; Wang B; Zhao Z; McMillin DW; Hu C; Li H; Wang J; Liang Y; Buhrlage SJ; Liang J; Liu J; Yang G; Brown JR; Treon SP; Mitsiades CS; Griffin JD; Liu Q; Gray NS
    ACS Chem Biol; 2014 May; 9(5):1086-91. PubMed ID: 24556163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.
    Boga SB; Alhassan AB; Liu J; Guiadeen D; Krikorian A; Gao X; Wang J; Yu Y; Anand R; Liu S; Yang C; Wu H; Cai J; Zhu H; Desai J; Maloney K; Gao YD; Fischmann TO; Presland J; Mansueto M; Xu Z; Leccese E; Knemeyer I; Garlisi CG; Bays N; Stivers P; Brandish PE; Hicks A; Cooper A; Kim RM; Kozlowski JA
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3939-3943. PubMed ID: 28720503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase as a drug discovery target.
    Pan Z
    Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
    Alinari L; Quinion C; Blum KA
    Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
    Seiler T; Dreyling M
    Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
    Wang Y; Zhang LL; Champlin RE; Wang ML
    Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
    Ge Y; Wang C; Song S; Huang J; Liu Z; Li Y; Meng Q; Zhang J; Yao J; Liu K; Ma X; Sun X
    Eur J Med Chem; 2018 Jan; 143():1847-1857. PubMed ID: 29146136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.
    Thakkar M; Bhuniya D; Kaduskar R; Mengawade T; Naik K; Salunkhe V; Bhalerao A; Kurhade S; Mavinahalli J; Jain V; Petla R; Avaragolla S; Ray S; Rouduri S; Dhanave A; De S; Pathade V; Tambe A; Raje AA; Madgula V; Joshi S; Nadeem A; Bala M; Umrani D; Hariharan N; Kulkarni B; Mookhtiar KA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1867-1873. PubMed ID: 28279528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
    Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.
    Wu H; Huang Q; Qi Z; Chen Y; Wang A; Chen C; Liang Q; Wang J; Chen W; Dong J; Yu K; Hu C; Wang W; Liu X; Deng Y; Wang L; Wang B; Li X; Gray NS; Liu J; Wei W; Liu Q
    Sci Rep; 2017 Mar; 7(1):466. PubMed ID: 28352114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
    Pan Z; Scheerens H; Li SJ; Schultz BE; Sprengeler PA; Burrill LC; Mendonca RV; Sweeney MD; Scott KC; Grothaus PG; Jeffery DA; Spoerke JM; Honigberg LA; Young PR; Dalrymple SA; Palmer JT
    ChemMedChem; 2007 Jan; 2(1):58-61. PubMed ID: 17154430
    [No Abstract]   [Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
    Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2016 Aug; 25(8):891-9. PubMed ID: 27148767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.
    Huynh T; Rodriguez-Rodriguez S; Danilov AV
    Mol Cancer Ther; 2024 May; 23(5):619-626. PubMed ID: 38693903
    [No Abstract]   [Full Text] [Related]  

  • 20. Recent advances in irreversible kinase inhibitors.
    Gilbert AM
    Pharm Pat Anal; 2014 Jul; 3(4):375-86. PubMed ID: 25291312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.